Depression Risk of 5-Alpha Reductase Inhibitors: Impact of Active-Comparator Versus Non-Drug User Control Groups on Risk Measurement

This meta-analysis of 5 studies with 2,517,859 patients found that 5-alpha reductase inhibitors (5-ARIs) for benign prostatic hyperplasia are associated with a minimal risk of depression. The study emphasizes that previous reports of increased depression risk may be due to inappropriate control group selection, as non-drug user controls can introduce bias. When comparing 5-ARI users to alpha-blocker users, who have similar disease burdens, the depression risk appears reduced by 10%. The findings suggest that the depression risk from 5-ARIs is minimal and should not significantly affect prescribing decisions. Future research should use active comparator designs to better address confounding factors.